Samsung Group in talks to buy U.S. drugmaker Biogen

Investing.com - Financial Markets Worldwide

Please try another search

EconomyDec 30, 2021 11:31AM ET

Samsung BioLogics says report on Biogen deal talks untrue© Reuters. FILE PHOTO: Employees of Samsung Group work at the company’s headquarters in Seoul April 22, 2008. REUTERS/Jo Yong-Hak

(Reuters) – Samsung (KS:) BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc (NASDAQ:).

Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.

Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was “not true,” without giving any more details.

Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.

Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics (OTC:) bought auto electronics maker Harman International Industries (D:) in an $8 billion deal.

Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.

In June, Biogen’s controversial Alzheimer’s drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel’s view that the company had not proven the treatment’s clinical benefits.

Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.

But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug’s high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.

Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.

Related Articles

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
The beginning of the year on the WSE.  CD Projekt is worth over PLN 20 billion again thumbnail

The beginning of the year on the WSE. CD Projekt is worth over PLN 20 billion again

2022-01-03 17:45publikacja2022-01-03 17:45/ CD ProjectInwestorzy powrócili do handlu na światowych giełdach. Stary rok żegnali w dobrych nastrojach i z takim samym nastawieniem przystąpili do handlu w nowym 2022 roku. Zachowanie warszawskich indeksów z ostatniego tygodnia ubiegłego roku idealnie wpasowało się w oczekiwany scenariusz wzrostów w ramach „rajdu św. Mikołaja” i tradycyjnych zwyżek podczas ostatnich sesji w…
Read More
Jobs saved as rival buys Eco Modular Buildings thumbnail

Jobs saved as rival buys Eco Modular Buildings

Industry ‘disruptor’ Spatial Initiative has bought troubled rival Eco Modular Buildings in a deal that saves more than 50 jobs. The Manchester firm, part of ESS Group, acquired the Hull-based offsite-construction specialist from administration. Eco Modular Buildings previously warned that it expected to make a loss in the current financial year and last month revealed
Read More
Encavis refinances project portfolio on better terms thumbnail

Encavis refinances project portfolio on better terms

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassenAlle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffenvom…
Read More
dpa-AFX CUSTOMER INFO: Financial analyzes in the dpa-AFX services thumbnail

dpa-AFX CUSTOMER INFO: Financial analyzes in the dpa-AFX services

FRANKFURT (dpa-AFX) - Alle Meldungen der Finanz-Nachrichtenagentur dpa-AFX werden mit journalistischer Sorgfalt erarbeitet. Bei der Erstellung der Meldungen wird regelmäßig das Sechs-Augen-Prinzip (Erstellung, Prüfung, zusätzliche Freigabe) angewendet. Jede/r Redakteur/in der dpa-AFX unterzeichnet einen internen Code of Conduct, der spezifische dpa-AFX Regelungen zur Wahrung der publizistischen Unabhängigkeit vorgibt und deren Einhaltung dpa-AFX individuell mit einem externen…
Read More
No plan to change Bengal board exam schedule thumbnail

No plan to change Bengal board exam schedule

There is no plan to change the schedule of upcoming offline board exams in West Bengal for now, given the fact that the dates decided upon are some three to four months away and the COVID-19 situation could improve by then, authorities said on Thursday. Class 12 exams are slated to be held from April…
Read More
These 3 Metaverse Coins Gained Over 1000% In the Past 24 Hours thumbnail

These 3 Metaverse Coins Gained Over 1000% In the Past 24 Hours

As crypto markets are looking for a bottom, with Bitcoin and Ethereum rebounding slightly today, some coins saw significant price gains of over 1000%. This article looks at the top three biggest gainers on CoinMarketCap today, ordered by 24-hour price gain, lowest to highest. PAPPAY (PAPPAY) +1069% Launched in April 2021, PAPPAY is a crypto…
Read More
Index Of News
Total
0
Share